Asset Details
Do you wish to reserve the book?
Clinical significance of steroid and xenobiotic receptor and its targeted gene CYP3A4 in human prostate cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical significance of steroid and xenobiotic receptor and its targeted gene CYP3A4 in human prostate cancer
Do you wish to request the book?
Clinical significance of steroid and xenobiotic receptor and its targeted gene CYP3A4 in human prostate cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical significance of steroid and xenobiotic receptor and its targeted gene CYP3A4 in human prostate cancer
2012
Overview
The steroid and xenobiotic receptor (SXR) regulates cytochrome P450 (CYP) enzymes, which are key inactivators of testosterone in the liver and prostate. In the present study, we investigated SXR expression in human prostate tissues. We determined SXR immunoreactivity using an anti‐SXR antibody in benign (n = 78) and cancerous (n = 106) tissues obtained by radical prostatectomy. Stained slides were evaluated for the proportion and staining intensity of immunoreactive cells. Total immunoreactivity (IR) scores (range: 0–8) were calculated as the sum of the proportion and intensity scores. Associations between the clinicopathological features of the patients, SXR status, and CYP3A4 immunoreactivity were analyzed. Western blot analyses validated the specificity of the anti‐SXR antibody in 293T cells transfected with pcDNA–FLAG–SXR. Positive (IR score: ≥ 2) nuclear SXR staining was observed in 91% (71/78) of benign foci and 47% (50/106) of cancerous lesions. Immunoreactivity scores were significantly lower in the cancerous lesions than in the benign foci (P < 0.0001). Clinicopathological analyses showed that cancer‐specific survival in patients with high SXR IR scores (≥4) was significantly increased (P = 0.046). Combined data of present and previous studies showed that high IR scores for both the SXR and CYP3A4 correlated with significantly better cancer‐specific survival rates in multivariate regression analyses (hazard ratio: 2.15, 95% confidence interval: 1.25–3.55, P = 0.007). We showed differential SXR expression in human prostate tissues. The high expression of the SXR and CYP3A4 is a strong prognostic indicator of favorable outcomes in prostate cancer, and could be a therapeutic target. (Cancer Sci 2012; 103: 176–180)
Publisher
Blackwell Publishing Ltd,John Wiley & Sons, Inc
Subject
/ Antigens
/ Biomarkers, Tumor - metabolism
/ Cancer
/ Cytochrome P-450 CYP3A - genetics
/ Cytochrome P-450 CYP3A - metabolism
/ Humans
/ Kinases
/ Ligands
/ Liver
/ Male
/ Patients
/ Prostate-Specific Antigen - blood
/ Prostatic Neoplasms - metabolism
/ Prostatic Neoplasms - mortality
/ Prostatic Neoplasms - pathology
/ Receptors, Steroid - biosynthesis
/ Receptors, Steroid - immunology
/ Receptors, Steroid - metabolism
/ Steroids
